मूलभूत आँकड़े
| LEI | 529900DZUWSYUURECK24 |
| CIK | 1429260 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Fortress Biotech, Inc.
SEC Filings (Chronological Order)
यह पृष्ठ SEC फाइलिंग की एक पूरी, कालानुक्रमिक सूची प्रदान करता है, ओनरशिप फाइलिंग को छोड़कर, जो हम अन्यत्र प्रदान करते हैं।
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-35366 FORT |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 14, 2025 Fortress Biotech, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-35366 (Commission File Number) 20 |
|
| August 14, 2025 |
Exhibit 99.1 Fortress Biotech Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights Fortress subsidiary Checkpoint Therapeutics acquired by Sun Pharma; Fortress received ~$28 million at closing and is eligible to receive up to an additional $4.8 million under a contingent value right (CVR), plus a 2.5% royalty on future net sales of UNLOXCYT™ (cosibelimab-ipdl) FDA accepted |
|
| August 1, 2025 |
6,189,786 Shares of Common Stock Filed Pursuant to Rule 424(b)(7) Registration No. 333-282384 PROSPECTUS SUPPLEMENT (to the Prospectus dated October 7, 2024) 6,189,786 Shares of Common Stock This prospectus supplement (“Prospectus Supplement”) supplements the prospectus dated October 7, 2024 (the “Base Prospectus”) relating to the resale by the selling stockholders (the “Selling Stockholders”) identified in this Base Prospectus u |
|
| July 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 16, 2025 Fortress Biotech, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-35366 (Commission File Number) 20-5 |
|
| June 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 17, 2025 Fortress Biotech, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-35366 (Commission File Number) 20-5 |
|
| June 5, 2025 |
Unaudited Pro Forma Consolidated Financial Statements Exhibit 99.1 Unaudited Pro Forma Consolidated Financial Statements As previously disclosed in the Current Report on Form 8-K filed by Fortress Biotech, Inc. (“Fortress” or the “Company”) with the Securities and Exchange Commission (the “SEC)” on March 10, 2025, Checkpoint Therapeutics, Inc., a Delaware corporation (“Checkpoint”) and subsidiary of Fortress, entered into an Agreement and Plan of Mer |
|
| June 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 30, 2025 Fortress Biotech, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-35366 (Commission File Number) 20-51 |
|
| May 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-35366 FOR |
|
| May 15, 2025 |
Exhibit 99.1 Fortress Biotech Reports First Quarter 2025 Financial Results and Recent Corporate Highlights Emrosi™ commercial launch initiated for the treatment of inflammatory lesions of rosacea in adults Fortress subsidiary Checkpoint Therapeutics to be acquired by Sun Pharma; special meeting of Checkpoint stockholders to approve the transaction to take place on May 28, 2025 FDA accepted New Dru |
|
| May 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 15, 2025 Fortress Biotech, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-35366 (Commission File Number) 20-51 |
|
| April 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 28, 2025 |
Table of Contents FORTRESS BIOTECH, INC. 1111 Kane Concourse, Suite 301 Bay Harbor Islands, FL 33154 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Prox |
|
| April 18, 2025 |
Table of Contents FORTRESS BIOTECH, INC. 1111 Kane Concourse, Suite 301 Bay Harbor Islands, FL 33154 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Prox |
|
| April 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 15, 2025 Fortress Biotech, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-35366 (Commission File Number) 20- |
|
| April 1, 2025 |
As filed with the Securities and Exchange Commission on March 31, 2025 As filed with the Securities and Exchange Commission on March 31, 2025 Registration No. |
|
| April 1, 2025 |
As filed with the Securities and Exchange Commission on March 31, 2025 As filed with the Securities and Exchange Commission on March 31, 2025 Registration No. |
|
| April 1, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Fortress Biotech, Inc. |
|
| April 1, 2025 |
As filed with the Securities and Exchange Commission on March 31, 2025 As filed with the Securities and Exchange Commission on March 31, 2025 Registration No. |
|
| April 1, 2025 |
As filed with the Securities and Exchange Commission on March 31, 2025 As filed with the Securities and Exchange Commission on March 31, 2025 Registration No. |
|
| April 1, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Fortress Biotech, Inc. |
|
| April 1, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Fortress Biotech, Inc. |
|
| April 1, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Fortress Biotech, Inc. |
|
| March 31, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 31, 2025 Fortress Biotech, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-35366 (Commission File Number) 20- |
|
| March 31, 2025 |
Exhibit 4.4 DESCRIPTION OF SECURITIES Fortress Biotech, Inc. (“we,” “our,” “the Company,” or “us) has two classes of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our common stock, with $0.0001 par value (“Common Stock”), and our 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock. The following descriptions of our Common Stock, preferred st |
|
| March 31, 2025 |
Exhibit 99.1 Fortress Biotech Reports 2024 Financial Results and Recent Corporate Highlights Emrosi™ approved by FDA for the treatment of inflammatory lesions of rosacea in adults, with commercial launch underway; initial distribution ongoing and first prescriptions filled Fortress subsidiary Checkpoint Therapeutics to be acquired by Sun Pharma; Checkpoint’s lead product, UNLOXCYT™, approved by FD |
|
| March 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to . Commission File No. 001-35366 FORTRESS |
|
| March 31, 2025 |
EXHIBIT 21.1 SUBSIDIARIES OF FORTRESS BIOTECH, INC. Subsidiaries of Fortress Biotech, Inc. at December 31, 2024, with jurisdiction of incorporation or formation: ● Aevitas Therapeutics, Inc. (Delaware) ● Avenue Therapeutics, Inc. (Delaware) ● Cellvation, Inc. (Delaware) ● Checkpoint Therapeutics, Inc. (Delaware) ● Cyprium Therapeutics, Inc. (Delaware) ● Helocyte, Inc. (Delaware) ● Journey Medical |
|
| March 31, 2025 |
Fortress Biotech, Inc. and Subsidiaries Insider Trading Policy.* Exhibit 19.1 FORTRESS BIOTECH, INC. AND SUBSIDIARIES INSIDER TRADING POLICY January 22, 2024 PERSONS COVERED This Insider Trading Policy applies to Fortress Biotech, Inc. (“Fortress”) and each of its publicly traded and private subsidiaries in which Fortress has a 50% or greater ownership interest or otherwise has a minority economic interest but majority voting interest. Fortress and each such su |
|
| March 10, 2025 |
Exhibit 10.2 ROYALTY AGREEMENT This Royalty Agreement (this “Agreement”) is made and entered into as of March 9, 2025 (the “Effective Date”) by and among Fortress Biotech, Inc., a Delaware corporation (“Fortress”), Sun Pharmaceutical Industries, Inc., a Delaware corporation (“Parent”), and Checkpoint Therapeutics, Inc., a Delaware corporation (“Checkpoint” and collectively with Parent, “Payor”). F |
|
| March 10, 2025 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 9, 2025 Fortress Biotech, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-35366 (Commission File Number) 20-5 |
|
| March 10, 2025 |
Exhibit 10.1 SUPPORT AGREEMENT This Support Agreement (this “Agreement”) is made and entered into as of March 9, 2025, by and among Sun Pharmaceutical Industries, Inc., a Delaware corporation (“Parent”), Fortress Biotech, Inc., a Delaware corporation (the “Stockholder”), and Checkpoint Therapeutics, Inc., a Delaware corporation (the “Company”). Recitals A.Concurrently with the execution and delive |
|
| March 10, 2025 |
Exhibit 2.1 AGREEMENT AND PLAN OF MERGER by and among CHECKPOINT THERAPEUTICS, INC., SUN PHARMACEUTICAL INDUSTRIES, INC. and SNOOPY MERGER SUB, INC. Dated as of March 9, 2025 TABLE OF CONTENTS Page ARTICLE I THE MERGER 2 Section 1.1 Merger of Merger Sub into the Company 2 Section 1.2 Effect of the Merger 2 Section 1.3 Closing; Effective Time. 3 Section 1.4 Certificate of Incorporation and Bylaws; |
|
| January 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 16, 2025 Fortress Biotech, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-35366 (Commission File Number) 2 |
|
| January 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 6, 2025 Fortress Biotech, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-35366 (Commission File Number) 20 |
|
| December 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 13, 2024 Fortress Biotech, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-35366 (Commission File Number) |
|
| November 15, 2024 |
ATXI / Avenue Therapeutics, Inc. / Fortress Biotech, Inc. - SC 13D/A Activist Investment SC 13D/A 1 tm2428627d1sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 5) Under the Securities Exchange Act of 1934 AVENUE THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.0001 Par Value (Title of Class of Securities) 05360L403 (CUSIP Number) Fortress Biotech, Inc. c/o Lindsay A. Rosenwald, M.D. 1111 Kane Concourse, Suite 3 |
|
| November 14, 2024 |
Exhibit 99.1 Fortress Biotech Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights Emrosi approved by FDA on November 4 for the treatment of inflammatory lesions of rosacea in adults Cosibelimab PDUFA goal date of December 28 for potential approval to treat metastatic or locally advanced cutaneous squamous cell carcinoma Miami, FL – November 14, 2024 – Fortress Biotech, Inc |
|
| November 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-35366 |
|
| November 14, 2024 |
Exhibit 10.4 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. ASSET PURCHASE AGREEMENT dated as of July 15, 2024 by and among CRYSTALYS THERAPEUTICS, INC. AND URICA THERAPEUTICS, INC. TABLE OF CONTENTS 1. DEFINITIONS1 2. PURCHASE |
|
| November 14, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 14, 2024 Fortress Biotech, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-35366 (Commission File Number) |
|
| November 14, 2024 |
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. |
|
| November 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 4, 2024 Fortress Biotech, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-35366 (Commission File Number) 2 |
|
| October 25, 2024 |
FBIO / Fortress Biotech, Inc. / HIGHBRIDGE CAPITAL MANAGEMENT LLC Passive Investment SC 13G 1 p24-3018sc13g.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Fortress Biotech, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 34960Q307 (CUSIP Number) September 30, 2024 (Date of event which requires filing of this statement) Check the appropriate box to d |
|
| October 25, 2024 |
Up to $6,500,000 of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-279516 AMENDMENT NO. 1 dated October 25, 2024 to PROSPECTUS SUPPLEMENT dated August 2, 2024 (to Prospectus dated May 30, 2024) Up to $6,500,000 of Common Stock This prospectus supplement (“Prospectus Supplement”) amends and supplements the information in our prospectus dated May 30, 2024 (the “Base Prospectus”), as supplemented by our prospectu |
|
| October 7, 2024 |
6,189,786 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-282384 PROSPECTUS 6,189,786 Shares of Common Stock This prospectus relates to the resale by the selling stockholders (the “Selling Stockholders”) identified in this prospectus under the section “The Selling Stockholders,” or their pledgees, donees, transferees or other successors in interest, from time to time, of (i) up to 506,390 shares of ou |
|
| October 2, 2024 |
Fortress Biotech, Inc. 1111 Kane Concourse, Suite 301 Bay Harbor Islands, Florida 33154 Fortress Biotech, Inc. 1111 Kane Concourse, Suite 301 Bay Harbor Islands, Florida 33154 VIA EDGAR October 2, 2024 Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attn: Joshua Gorsky Re: Fortress Biotech, Inc. Registration Statement on Form S-1 File No. 333-282384 Request for Acceleration of Effective Date Ladies a |
|
| October 1, 2024 |
CKPT / Checkpoint Therapeutics, Inc. / Fortress Biotech, Inc. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 8) Under the Securities Exchange Act of 1934 CHECKPOINT THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.0001 Par Value Class A Common Stock, $0.0001 Par Value (Title of Class of Securities) 162828 206 (CUSIP Number) Fortress Biotech, Inc. c/o Lindsay A. Rosenwald, M.D. 1111 Kane Concourse, Suit |
|
| September 27, 2024 |
Exhibit 107 CALCULATION OF FILING FEE TABLES FORM S-1 (Form Type) FORTRESS BIOTECH, INC. |
|
| September 27, 2024 |
As filed with the Securities and Exchange Commission on September 27, 2024 As filed with the Securities and Exchange Commission on September 27, 2024 Registration No. |
|
| September 27, 2024 |
Exhibit 4.8 CONFIDENTIAL Form of WARRANT NEITHER THIS WARRANT NOR THE SECURITIES ISSUABLE UPON ITS EXERCISE OR CONVERSION HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY APPLICABLE STATE SECURITIES LAW AND MAY NOT BE TRANSFERRED EXCEPT (I) IN ACCORDANCE WITH THE SECURITIES ACT OR SUCH APPLICABLE STATE SECURITIES LAWS, PURSUANT TO REGISTRATION OR EXE |
|
| September 27, 2024 |
Exhibit 10.34 Execution Version CREDIT AGREEMENT dated as of July 25, 2024 by and among FORTRESS BIOTECH, INC., as the Borrower, THE LENDERS FROM TIME TO TIME PARTY HERETO as the Lenders, and OAKTREE FUND ADMINISTRATION, LLC, as the Administrative Agent U.S. $50,000,000 TABLE OF CONTENTS Section 1. DEFINITIONS 1 1.01 Certain Defined Terms 1 1.02 Accounting Terms and Principles 27 1.03 Interpretati |
|
| September 25, 2024 |
FBIO / Fortress Biotech, Inc. / ROSENWALD LINDSAY A MD - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 4)* Under the Securities Exchange Act of 1934 FORTRESS BIOTECH, INC. (Name of Issuer) Common Stock, $0.001 Par Value (Title of Class of Securities) 34960Q 307 (CUSIP Number) Lindsay A. Rosenwald, M.D. 1111 Kane Concourse, Suite 301 Bay Harbor Islands, FL 33154 (781) 652-4500 (Name, Address and Telep |
|
| September 23, 2024 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| September 23, 2024 |
Exhibit 10.3 Placement Agency Agreement September 19, 2024 Fortress Biotech, Inc. 1111 Kane Concourse, Suite 301 Bay Harbor Islands, FL 33154 Attn: Chief Executive Officer Dear Mr. Lindsay A. Rosenwald, M.D.: This letter (the “Agreement”) constitutes the agreement between A.G.P./Alliance Global Partners (the “Placement Agent”) and Fortress Biotech, Inc., a Delaware corporation (the “Company”), tha |
|
| September 23, 2024 |
Exhibit 10.2 LOCK-UP AGREEMENT September , 2024 A.G.P./Alliance Global Partners 590 Madison Avenue, 28th Floor New York, New York 10022 Re: Fortress Biotech, Inc., Proposed Offering Ladies and Gentlemen: The undersigned understands that you (“AGP” or the “Placement Agent”) propose to enter into a Placement Agency Agreement, to be dated as of September 2024 (the “Placement Agency Agreement”) by and |
|
| September 23, 2024 |
Exhibit 99.1 Fortress Biotech Announces Pricing of $8 Million Registered Direct Offering and Concurrent Private Placements Miami, FL – September 20, 2024 – Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress” or “Company”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend |
|
| September 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 19, 2024 Fortress Biotech, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35366 20-5157386 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| September 23, 2024 |
3,939,394 Shares of Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-279516 PROSPECTUS SUPPLEMENT (to the Prospectus dated May 30, 2024) 3,939,394 Shares of Common Stock Pursuant to this prospectus supplement, the accompanying prospectus and the securities purchase agreements dated September 19, 2024 (the “Securities Purchase Agreements”), we are offering 3,939,394 shares of our common stock, par value $0.001 pe |
|
| September 23, 2024 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of September [∙], 2024, between Fortress Biotech, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and condit |
|
| September 20, 2024 |
The date of this prospectus supplement is September 19, 2024. Filed Pursuant to Rule 424(b)(5) Registration No. 333-279516 PROSPECTUS SUPPLEMENT (To Prospectus Supplement dated August 2, 2024 and Prospectus dated May 30, 2024) This prospectus supplement supplements and amends certain information contained in the prospectus dated May 30, 2024 (the “Base Prospectus”), as supplemented by our prospectus supplement dated August 2, 2024 (the “Prospectus Suppleme |
|
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-35366 FORT |
|
| August 13, 2024 |
Fortress Biotech Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights PDUFA goal date of November 4, 2024 for DFD-29 for the treatment of inflammatory lesions and erythema of rosacea in adults FDA accepted Biologics License Application resubmission for cosibelimab to treat metastatic or locally advanced cutaneous squamous cell carcinoma; PDUFA goal date of December 28, 2024 Miami, FL – August 13, 2024 – Fortress Biotech, Inc. |
|
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 13, 2024 Fortress Biotech, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-35366 (Commission File Number) 20 |
|
| August 2, 2024 |
Up to $13,000,000 Shares of Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-279516 PROSPECTUS SUPPLEMENT (to the Prospectus dated May 30, 2024) Up to $13,000,000 Shares of Common Stock In accordance with the terms of the At Market Issuance Sales Agreement entered into with H.C. Wainwright & Co., LLC (“Wainwright”) and Dawson James Securities, Inc. (“Dawson James”) (each, an “Agent” and together, the “Agents”), dated Ma |
|
| July 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 25, 2024 Fortress Biotech, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-35366 (Commission File Number) 20-5 |
|
| July 25, 2024 |
Exhibit 99.1 Fortress Biotech Reduces Total Debt and Enters into New $35 Million Term Loan with Oaktree with Maturity in 2027 Extends maturity of long-term debt as Fortress’ late-stage pipeline continues to advance and may generate up to three regulatory approvals on NDAs and BLAs in the next 12 months and potentially a fourth BLA filing as early as 2025 Miami, FL – July 25, 2024 – Fortress Biotec |
|
| July 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 15, 2024 Fortress Biotech, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-35366 (Commission File Number) 20-5 |
|
| July 5, 2024 |
Exhibit 99.1 Fortress Biotech Announces Pause in Payment of Dividends on 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock Miami, FL – July 5, 2024 – Fortress Biotech, Inc. (Nasdaq: FBIO; FBIOP) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and divide |
|
| July 5, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 5, 2024 Fortress Biotech, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-35366 (Commission File Number) 20-51 |
|
| June 28, 2024 |
MBIO / Mustang Bio, Inc. / Fortress Biotech, Inc. - SC 13D/A Activist Investment SC 13D/A 1 tm2418563d1sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 3) Under the Securities Exchange Act of 1934 MUSTANG BIO, INC. (Name of Issuer) Common Stock, $0.0001 Par Value (Title of Class of Securities) 62818Q203 (CUSIP Number) Fortress Biotech, Inc. c/o Lindsay A. Rosenwald, M.D. 1111 Kane Concourse, Suite 301 Bay H |
|
| June 28, 2024 |
Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 27, 2024 Fortress Biotech, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-35366 (Commission File Number) 20-5 |
|
| June 27, 2024 |
2,353,393 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-280342 PROSPECTUS 2,353,393 Shares of Common Stock This prospectus relates to the resale by the selling stockholders (the “Selling Stockholders”) identified in this prospectus under the section “The Selling Stockholders,” or their pledgees, donees, transferees or other successors in interest, from time to time, of (i) up to 95,160 shares of our |
|
| June 25, 2024 |
Exhibit 3.2 FOURTH AMENDED AND RESTATED BYLAWS OF FORTRESS BIOTECH, INC. Adopted June 19, 2024 ARTICLE I OFFICES SECTION 1. Principal Office. The registered office of Fortress Biotech, Inc. (the “Corporation”) shall be located in such place as may be provided from time to time in the Certificate of Incorporation. SECTION 2. Other Offices. The Corporation may also have offices at such other places |
|
| June 25, 2024 |
Amendments to Second Amended and Restated Bylaws of the Company Exhibit 3.1 THIRDFOURTH AMENDED AND RESTATED BY-LAWS OF FORTRESS BIOTECH, INC. (FORMERLY CORONADO BIOSCIENCES, INC.) Adopted August 10June [●], 20234 ARTICLE I OFFICES SECTION 1. Principal Office. The registered office of the Fortress Biotech, Inc. (the “cCorporation”) shall be located in such place as may be provided from time to time in the Certificate of Incorporation. SECTION 2. Other Offices. |
|
| June 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 19, 2024 Fortress Biotech, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-35366 (Commission File Number) 20-5 |
|
| June 25, 2024 |
Fortress Biotech, Inc. 1111 Kane Concourse, Suite 301 Bay Harbor Islands, Florida 33154 Fortress Biotech, Inc. 1111 Kane Concourse, Suite 301 Bay Harbor Islands, Florida 33154 VIA EDGAR June 25, 2024 Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attn: Tyler Howes Re: Fortress Biotech, Inc. Registration Statement on Form S-3 File No. 333-280342 Request for Acceleration of Effective Date Ladies and |
|
| June 20, 2024 |
Exhibit 107 CALCULATION OF FILING FEE TABLES FORM S-3 (Form Type) FORTRESS BIOTECH, INC. |
|
| June 20, 2024 |
As filed with the Securities and Exchange Commission on June 20, 2024 Registration No. |
|
| May 31, 2024 |
As filed with the Securities and Exchange Commission on May 31, 2024 As filed with the Securities and Exchange Commission on May 31, 2024 Registration No. |
|
| May 31, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Fortress Biotech, Inc. |
|
| May 31, 2024 |
As filed with the Securities and Exchange Commission on May 31, 2024 As filed with the Securities and Exchange Commission on May 31, 2024 Registration No. |
|
| May 31, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Fortress Biotech, Inc. |
|
| May 31, 2024 |
$50,000,000 Common Stock Preferred Stock Warrants Debt Securities Filed Pursuant to Rule 424(b)(5) Registration No. 333-279516 PROSPECTUS $50,000,000 Common Stock Preferred Stock Warrants Debt Securities Units The following are types of securities that we may offer, issue and sell from time to time, together or separately: · shares of our common stock; · shares of our preferred stock; · warrants; · debt securities; and · units consisting of any combination of ou |
|
| May 29, 2024 |
Fortress Biotech, Inc. 1111 Kane Concourse, Suite 301 Bay Harbor Islands, Florida 33154 Fortress Biotech, Inc. 1111 Kane Concourse, Suite 301 Bay Harbor Islands, Florida 33154 VIA EDGAR May 29, 2024 Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attn: Lauren Hamill Re: Fortress Biotech, Inc. Registration Statement on Form S-3 File No. 333-279516 Request for Acceleration of Effective Date Ladies and |
|
| May 29, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Fortress Biotech, Inc. |
|
| May 29, 2024 |
As filed with the Securities and Exchange Commission on May 29, 2024 As filed with the Securities and Exchange Commission on May 29, 2024 Registration Statement No. |
|
| May 29, 2024 |
Exhibit 10.3 AMENDMENT TO THE FORTRESS BIOTECH, INC. AMENDED AND RESTATED LONG TERM INCENTIVE PLAN This amendment (the “Amendment”) to the Fortress Biotech, Inc. Amended and Restated Long Term Incentive Plan (the “LTIP”), is hereby adopted this 23rd day of May, 2024, by the Board of Directors (the “Board”) of Fortress Biotech, Inc. (the “Company”). WITNESSETH: WHEREAS, the Company adopted the LTIP |
|
| May 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 23, 2024 Fortress Biotech, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35366 20-5157386 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| May 29, 2024 |
Exhibit 10.2 AMENDMENT TO THE FORTRESS BIOTECH, INC. 2012 EMPLOYEE STOCK PURCHASE PLAN This amendment (the “Amendment”) to the Fortress Biotech, Inc. 2012 Employee Stock Purchase Plan, as amended (the “Plan”), is hereby adopted this 23rd day of May, 2024, by the Board of Directors (the “Board”) of Fortress Biotech, Inc. (the “Company”). WITNESSETH: WHEREAS, the Company adopted the Plan for the pur |
|
| May 29, 2024 |
Exhibit 10.1 AMENDMENT TO THE COMPANY’S 2013 STOCK INCENTIVE PLAN TO INCREASE THE NUMBER OF SHARES OF COMMON STOCK AUTHORIZED FOR ISSUANCE THEREUNDER 1. Section 3(a) of the 2013 Plan is hereby replaced in its entirety so that such section reads as follows: 3. STOCK SUBJECT TO THE PLAN (a) Subject to the provisions of Section 12 below, the maximum aggregate number of Shares which may be issued purs |
|
| May 17, 2024 |
CKPT / Checkpoint Therapeutics, Inc. / Fortress Biotech, Inc. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 7) Under the Securities Exchange Act of 1934 CHECKPOINT THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.0001 Par Value Class A Common Stock, $0.0001 Par Value (Title of Class of Securities) 162828 206 (CUSIP Number) Fortress Biotech, Inc. c/o Lindsay A. Rosenwald, M.D. 1111 Kane Concourse, Suit |
|
| May 17, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Fortress Biotech, Inc. |
|
| May 17, 2024 |
Form of Indenture, between the Registrant and one or more trustees to be named. Exhibit 4.7 FORTRESS BIOTECH, INC. and Trustee INDENTURE Dated as of DEBT SECURITIES CROSS-REFERENCE TABLE(1) Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.01 4.04 312(b) 4.04(c) 312(c) 4.04(c) 313(a) 4.03 313(b) 4.03 313(c) 4.03 313(d) 4.03 314(a) 3.05 and 4.02 314(b) In |
|
| May 17, 2024 |
As filed with the Securities and Exchange Commission on May 17, 2024 As filed with the Securities and Exchange Commission on May 17, 2024 Registration Statement No. |
|
| May 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-35366 FOR |
|
| May 15, 2024 |
Exhibit 99.1 Fortress Biotech Reports First Quarter 2024 Financial Results and Recent Corporate Highlights Fortress‘ late-stage pipeline continues to advance and may generate up to three regulatory approvals on NDAs and BLAs in the next 12 months and potentially a fourth BLA filing as early as 2025 FDA accepted New Drug Application filing for DFD-29 to treat inflammatory lesions and erythema of ro |
|
| May 15, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2024 Fortress Biotech, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35366 20-5157386 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| April 17, 2024 |
ATXI / Avenue Therapeutics, Inc. / Fortress Biotech, Inc. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 4) Under the Securities Exchange Act of 1934 AVENUE THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.0001 Par Value (Title of Class of Securities) 05360L304 (CUSIP Number) Fortress Biotech, Inc. c/o Lindsay A. Rosenwald, M.D. 1111 Kane Concourse, Suite 301 Bay Harbor Islands, FL 33154 (781) 652- |
|
| April 5, 2024 |
Fortress Biotech, Inc. Up to $11,958,791 Common Stock PROSPECTUS SUPPLEMENT Filed Pursuant to Rule 424(b)(3) (To Prospectus Supplement dated May 26, 2023 and Prospectus dated July 30, 2021) Registration No. |
|
| April 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 5, 2024 |
Table of Contents This i FORTRESS BIOTECH, INC. 1111 Kane Concourse Suite 301 Bay Harbor Islands, FL 33154 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminar |
|
| March 28, 2024 |
Exhibit 99.1 Fortress Biotech Reports 2023 Financial Results and Recent Corporate Highlights Record consolidated net revenue of $84.5 million for full-year 2023 Fortress may receive up to four regulatory decisions on NDAs and BLAs in the next 18 months FDA accepted New Drug Application filing for DFD-29 to treat inflammatory lesions and erythema of rosacea in adults; PDUFA goal date of November 4, |
|
| March 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to . Commission File No. 001-35366 FORTRESS |
|
| March 28, 2024 |
Clawback Policy of Fortress Biotech, Inc.* Exhibit 97.1 FORTRESS BIOTECH, INC. Clawback Policy Effective as of October 2, 2023 The Board of Directors (“Board”) of Fortress Biotech, Inc. (“Company”) believes that it is in the best interests of the Company and its shareholders to adopt this Clawback Policy (“Policy”) which provides for the recoupment of certain executive compensation in the event of an Accounting Restatement (as defined belo |
|
| March 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2024 Fortress Biotech, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35366 20-5157386 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| March 28, 2024 |
Description of Securities of Fortress Biotech, Inc.* Exhibit 4.4 DESCRIPTION OF SECURITIES Fortress Biotech, Inc. (“we,” “our,” “the Company,” or “us) has two classes of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our common stock, with $0.0001 par value (“Common Stock”) and our 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock. The following descriptions of our Common Stock, preferred sto |
|
| March 28, 2024 |
Subsidiaries of the Registrant. * EXHIBIT 21.1 SUBSIDIARIES OF FORTRESS BIOTECH, INC. Subsidiaries of Fortress Biotech, Inc. at December 31, 2023, with jurisdiction of incorporation or formation: ● Aevitas Therapeutics, Inc. (Delaware) ● Avenue Therapeutics, Inc. (Delaware) ● Cellvation, Inc. (Delaware) ● Checkpoint Therapeutics, Inc. (Delaware) ● Cyprium Therapeutics, Inc. (Delaware) ● Helocyte, Inc. (Delaware) ● Journey Medical |
|
| March 22, 2024 |
CKPT / Checkpoint Therapeutics, Inc. / Fortress Biotech, Inc. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 6) Under the Securities Exchange Act of 1934 CHECKPOINT THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.0001 Par Value Class A Common Stock, $0.0001 Par Value (Title of Class of Securities) 162828 206 (CUSIP Number) Fortress Biotech, Inc. c/o Lindsay A. Rosenwald, M.D. 1111 Kane Concourse, Suit |
|
| February 14, 2024 |
FBIO / Fortress Biotech, Inc. / Nantahala Capital Management, LLC - SC 13G/A Passive Investment SC 13G/A 1 tm243309d3sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Fortress Biotech, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 34960Q109 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to d |
|
| January 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Sections 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 25, 2024 Fortress Biotech, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35366 20-5157386 (State or other jurisdiction of incorporation) (Commissio |
|
| January 3, 2024 |
Exhibit 4.1 COMMON STOCK PURCHASE WARRANT Fortress biotech, inc. Warrant Shares: Initial Exercise Date: January 3, 2024 Issue Date: January 3, 2029 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its registered assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time |
|
| January 3, 2024 |
Exhibit 99.1 Fortress Biotech Announces Pricing of $11 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Miami, FL – December 29, 2023 – Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress” or “Company”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, |
|
| January 3, 2024 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-258145 PROSPECTUS SUPPLEMENT (to the Prospectus dated July 30, 2021) 3,303,305 Units, Each Consisting of One Share of Common Stock and One Warrant to Purchase One Share of Common Stock and 3,303,305 Shares of Common Stock Underlying the Warrants Pursuant to this prospectus supplement, the accompanying prospectus and the securities purchase agre |
|
| January 3, 2024 |
Exhibit 107 The prospectus to which this Exhibit is attached is a final prospectus for the related offering. The maximum aggregate offering price for such offering is $21,603,614.70. |
|
| January 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Sections 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 29, 2023 Fortress Biotech, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-35366 (Commission File Num |
|
| January 3, 2024 |
US34960Q3074 / Fortress Biotech, Inc. / ROSENWALD LINDSAY A MD - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 3)* Under the Securities Exchange Act of 1934 FORTRESS BIOTECH, INC. (Name of Issuer) Common Stock, $0.001 Par Value (Title of Class of Securities) 34960Q 307 (CUSIP Number) Lindsay A. Rosenwald, M.D. 1111 Kane Concourse Suite 301 Bay Harbor Islands, FL 33154 (781) 652-4500 (Name, Address and Teleph |
|
| January 3, 2024 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of , 2023, between Fortress Biotech, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions |
|
| January 3, 2024 |
Exhibit 10.2 PLACEMENT AGENCY AGREEMENT December 29, 2023 Roth Capital Partners, LLC 888 San Clemente Drive, Suite 400 Newport Beach, CA 92660 Ladies and Gentlemen: Introduction. Subject to the terms and conditions herein (this “Agreement”), Fortress Biotech, Inc., a Delaware corporation (the “Company”), hereby agrees to sell up to an aggregate of $11,000,005.65 of registered securities of the Com |
|
| January 3, 2024 |
Exhibit 99.2 Fortress Biotech Announces Closing of $11 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Miami, FL – January 3, 2024 – Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress” or “Company”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, t |
|
| November 21, 2023 |
US34960Q3074 / Fortress Biotech, Inc. / WEISS MICHAEL S - SC 13D/A Activist Investment SC 13D/A 1 tm2331249d2sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 4)* Under the Securities Exchange Act of 1934 FORTRESS BIOTECH, INC. (Name of Issuer) Common Stock, $0.001 Par Value (Title of Class of Securities) 34960Q 307 (CUSIP Number) Michael S. Weiss 1111 Kane Concourse Suite 301 Bay Harbor Islands, FL 33154 (781) 65 |
|
| November 21, 2023 |
US34960Q3074 / Fortress Biotech, Inc. / ROSENWALD LINDSAY A MD - SC 13D/A Activist Investment SC 13D/A 1 tm2331249d1sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 2)* Under the Securities Exchange Act of 1934 FORTRESS BIOTECH, INC. (Name of Issuer) Common Stock, $0.001 Par Value (Title of Class of Securities) 34960Q 307 (CUSIP Number) Lindsay A. Rosenwald, M.D. 1111 Kane Concourse Suite 301 Bay Harbor Islands, FL 3315 |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-35366 |
|
| November 14, 2023 |
Fortress Biotech Announces Closing of $10.0 Million Public Offering Exhibit 99.3 Fortress Biotech Announces Closing of $10.0 Million Public Offering Miami, FL – November 14, 2023 – Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress” or “Company”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today announced the closing of its previously an |
|
| November 14, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 14, 2023 Fortress Biotech, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-35366 (Commission File Number) |
|
| November 14, 2023 |
Exhibit 10.1 FORM OF SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of November 10, 2023, between Fortress Biotech, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and |
|
| November 14, 2023 |
Fortress Biotech Announces Pricing of $10.0 Million Public Offering Exhibit 99.2 Fortress Biotech Announces Pricing of $10.0 Million Public Offering Miami, FL – November 10, 2023 – Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress” or “Company”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today announced the pricing of its public offeri |
|
| November 14, 2023 |
Exhibit 10.2 FORM OF PLACEMENT AGENCY AGREEMENT November 10, 2023 Roth Capital Partners, LLC 888 San Clemente Drive, Suite 400 Newport Beach, CA 92660 Ladies and Gentlemen: Introduction. Subject to the terms and conditions herein (this “Agreement”), Fortress Biotech, Inc., a Delaware corporation (the “Company”), hereby agrees to sell up to an aggregate of $10,004,500.00 of registered securities of |
|
| November 14, 2023 |
Fortress Biotech Announces Launch of Proposed Public Offering Exhibit 99.1 Fortress Biotech Announces Launch of Proposed Public Offering Miami, FL – November 9, 2023 – Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress” or “Company”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today announced that it has commenced a public offering |
|
| November 14, 2023 |
Exhibit 4.1 FORM OF COMMON STOCK PURCHASE WARRANT Fortress biotech, inc. Warrant Shares: Initial Exercise Date: November 14, 2023 Issue Date: November 14, 2023 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its registered assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, |
|
| November 14, 2023 |
Exhibit 99.1 Fortress Biotech Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights Total consolidated net revenue was $34.8 million in the third quarter of 2023, a 100% increase from total consolidated net revenue of $17.4 million in the second quarter of 2023 Fortress is advancing several late-stage clinical assets with three potential NDA and BLA submissions to FDA throug |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Sections 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2023 Fortress Biotech, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-35366 (Commission File Numb |
|
| November 13, 2023 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-258145 PROSPECTUS SUPPLEMENT (to the Prospectus dated July 30, 2021) 5,885,000 Units, Each Consisting of One Share of Common Stock and One Warrant to Purchase One Share of Common Stock and 5,885,000 Shares of Common Stock Underlying the Warrants We are offering on a best efforts basis 5,885,000 units, each consisting of one share of our commo |
|
| November 9, 2023 |
Subject to completion, dated November 9, 2023 Filed Pursuant to Rule 424(b)(5) Registration No. 333-258145 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities |
|
| October 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 24, 2023 Fortress Biotech, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-35366 (Commission File Number) 2 |
|
| October 26, 2023 |
October 26, 2023 VIA EDGAR Frank Wyman and Li Xiao Division of Corporation Finance Office of Life Sciences United States Securities and Exchange Commission 100 F Street, N. |
|
| October 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 9, 2023 Fortress Biotech, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-35366 (Commission File Number) 20 |
|
| October 10, 2023 |
Fortress Biotech Announces Reverse Stock Split Exhibit 99.1 Fortress Biotech Announces Reverse Stock Split Miami, FL – October 9, 2023 – Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress” or the “Company”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, announced that it will effect a 1-for-15 reverse stock split of its |
|
| October 10, 2023 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT OF THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION, AS AMENDED, OF FORTRESS BIOTECH, INC. Fortress Biotech, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the Delaware General Corporation Law (the “DGCL”), does hereby certify: 1. The amendments as set forth in such resolutions are as follows. The Amended and Restated |
|
| September 29, 2023 |
As filed with the Securities and Exchange Commission on September 29, 2023 As filed with the Securities and Exchange Commission on September 29, 2023 Registration No. |
|
| September 29, 2023 |
Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) Fortress Biotech, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule(1) Amount Registered(2) Proposed Maximum Offering Price Per Unit(1) Maximum Aggregate Offering Price(1) Fee Rate Amount of Registration Fee Equity Common Stock, |
|
| September 29, 2023 |
As filed with the Securities and Exchange Commission on September 29, 2023 As filed with the Securities and Exchange Commission on September 29, 2023 Registration No. |
|
| September 29, 2023 |
Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) Fortress Biotech, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule(1) Amount Registered(2) Proposed Maximum Offering Price Per Unit(1) Maximum Aggregate Offering Price(1) Fee Rate Amount of Registration Fee Equity Common Stock, |
|
| September 26, 2023 |
US1628282063 / CHECKPOINT THERAPEUTICS INC / Fortress Biotech, Inc. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 5) Under the Securities Exchange Act of 1934 CHECKPOINT THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.0001 Par Value Class A Common Stock, $0.0001 Par Value (Title of Class of Securities) 162828 206 (CUSIP Number) Fortress Biotech, Inc. c/o Lindsay A. Rosenwald, M.D. 1111 Kane Concourse, Suit |
|
| September 18, 2023 |
US05360L3042 / Avenue Therapeutics Inc / Fortress Biotech, Inc. - SC 13D/A Activist Investment SC 13D/A 1 tm2326316d1sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 3) Under the Securities Exchange Act of 1934 AVENUE THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.0001 Par Value (Title of Class of Securities) 05360L304 (CUSIP Number) Fortress Biotech, Inc. c/o Lindsay A. Rosenwald, M.D. 1111 Kane Concourse, Suite 3 |
|
| August 25, 2023 |
FORTRESS BIOTECH, INC. 1111 Kane Concourse, Suite 301 Bay Harbor Islands, FL 33154 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Conf |
|
| August 25, 2023 |
FORTRESS BIOTECH, INC. 1111 Kane Concourse, Suite 301 Bay Harbor Islands, FL 33154 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Conf |
|
| August 15, 2023 |
FORTRESS BIOTECH, INC. 1111 Kane Concourse, Suite 301 Bay Harbor Islands, FL 33154 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: x Preliminary Proxy Statement ¨ Conf |
|
| August 14, 2023 |
Amendments to Second Amended and Restated Bylaws of the Company Exhibit 3.1 Amendments to Second Amended and Restated Bylaws The text below reflects modifications reflected in the Third Amended and Restated Bylaws of Fortress Biotech, Inc., with additions (in red) and deletions (in red strikethrough): ARTICLE II STOCKHOLDERS SECTION 5. Voting Process. If a quorum is present or represented, the affirmative vote of a majority of the shares of stock present or re |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 10, 2023 Fortress Biotech, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-35366 (Commission File Number) 20 |
|
| August 14, 2023 |
Exhibit 99.1 Fortress Biotech Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights Total net revenue was $17.4 million in the second quarter of 2023, a 40% increase from $12.4 million in the first quarter of 2023 Positive topline results from two Phase 3 clinical trials evaluating DFD-29 demonstrated achievement of co-primary and all secondary endpoints versus placebo and |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-35366 FORT |
|
| August 14, 2023 |
Exhibit 3.2 THIRD AMENDED AND RESTATED BYLAWS OF FORTRESS BIOTECH, INC. — A Delaware Corporation — THIRD AMENDED AND RESTATED BY-LAWS OF FORTRESS BIOTECH, INC. (FORMERLY CORONADO BIOSCIENCES, INC.) Adopted August 10, 2023 ARTICLE I OFFICES SECTION 1. Principal Office. The registered office of the corporation shall be located in such place as may be provided from time to time in the Certificate of |
|
| July 18, 2023 |
July 18, 2023 VIA EDGAR Frank Wyman and Li Xiao Division of Corporation Finance Office of Life Sciences United States Securities and Exchange Commission 100 F Street, N. |
|
| July 6, 2023 |
US1628282063 / CHECKPOINT THERAPEUTICS INC / Fortress Biotech, Inc. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 4) Under the Securities Exchange Act of 1934 CHECKPOINT THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.0001 Par Value Class A Common Stock, $0.0001 Par Value (Title of Class of Securities) 162828 206 (CUSIP Number) Fortress Biotech, Inc. c/o Lindsay A. Rosenwald, M.D. 1111 Kane Concourse, Suit |
|
| June 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 21, 2023 Fortress Biotech, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-35366 (Commission File Number) 20-5 |
|
| June 23, 2023 |
Exhibit 10.1 AMENDMENT TO THE COMPANY’S 2013 STOCK INCENTIVE PLAN TO INCREASE THE NUMBER OF SHARES OF COMMON STOCK AUTHORIZED FOR ISSUANCE THEREUNDER 3. STOCK SUBJECT TO THE PLAN (a) Subject to the provisions of Section 12 below, the maximum aggregate number of Shares which may be issued pursuant to all Awards (including Incentive Stock Options) is Twenty-Three Million (23,000,000) Shares. The Sha |
|
| June 23, 2023 |
Exhibit 10.2 SECOND AMENDMENT TO THE FORTRESS BIOTECH, INC. 2012 EMPLOYEE STOCK PURCHASE PLAN This amendment (the “Amendment”) to the Fortress Biotech, Inc. 2012 Employee Stock Purchase Plan, as amended (the “Plan”), is hereby adopted this 28th day of April, 2023, by the Board of Directors (the “Board”) of Fortress Biotech, Inc. (the “Company”). WITNESETH: WHEREAS, the Company adopted the Plan for |
|
| June 16, 2023 |
Exhibit 4.1 FORM OF AMENDED & RESTATED WARRANT NEITHER THIS WARRANT NOR THE SECURITIES ISSUABLE UPON ITS EXERCISE OR CONVERSION HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY APPLICABLE STATE SECURITIES LAW AND MAY NOT BE TRANSFERRED EXCEPT (I) IN ACCORDANCE WITH THE SECURITIES ACT OR SUCH APPLICABLE STATE SECURITIES LAWS, PURSUANT TO REGISTRATION |
|
| June 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 13, 2023 Fortress Biotech, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-35366 (Commission File Number) 20-5 |
|
| May 26, 2023 |
Up to $40,000,000 Shares of Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-258145 PROSPECTUS SUPPLEMENT (to the Prospectus dated July 30, 2021) Up to $40,000,000 Shares of Common Stock In accordance with the terms of the At Market Issuance Sales Agreement entered into with Cantor Fitzgerald & Co. (“Cantor”), H.C. Wainwright & Co., LLC (“Wainwright”), B. Riley Securities, Inc. (formerly B. Riley FBR, Inc.) (“B. Riley |
|
| May 15, 2023 |
Exhibit 99.1 Fortress Biotech Reports First Quarter 2023 Financial Results and Recent Corporate Highlights Fortress is advancing several late-stage clinical assets with two NDA submissions anticipated in second half of 2023 PDUFA goal date of January 3, 2024 set by FDA for cosibelimab to treat metastatic or locally advanced cutaneous squamous cell carcinoma Miami, FL – May 15, 2023 – Fortress Biot |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-35366 FOR |
|
| May 15, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 15, 2023 Fortress Biotech, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-35366 (Commission File Number) 20-51 |
|
| May 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 2, 2023 Fortress Biotech, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-35366 (Commission File Number) 20-515 |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 28, 2023 |
Table of Contents FORTRESS BIOTECH, INC. 1111 Kane Concourse Suite 301 Bay Harbor Islands, FL 33154 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy |
|
| April 19, 2023 |
US1628282063 / CHECKPOINT THERAPEUTICS INC / Fortress Biotech, Inc. - SC 13D/A Activist Investment SC 13D/A 1 tm2313235d1sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 3) Under the Securities Exchange Act of 1934 CHECKPOINT THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.0001 Par Value Class A Common Stock, $0.0001 Par Value (Title of Class of Securities) 162828 206 (CUSIP Number) Fortress Biotech, Inc. c/o Lindsay A. |
|
| April 13, 2023 |
April 13, 2023 VIA EDGAR Division of Corporation Finance United States Securities and Exchange Commission 100 F Street, N. |
|
| April 13, 2023 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 10, 2023 Fortress Biotech, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-35366 (Commission File Number) 20- |
|
| April 7, 2023 |
As filed with the Securities and Exchange Commission on April 7, 2023 As filed with the Securities and Exchange Commission on April 7, 2023 Registration No. |
|
| March 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to . Commission File No. 001-35366 FORTRESS |
|
| March 31, 2023 |
Exhibit 4.3 to the 2022 Form 10-K Exhibit 4.3 DESCRIPTION OF SECURITIES When used herein, the terms “we,” “our,” “the Company,” and “us” refer to Fortress Biotech, Inc. DESCRIPTION OF CAPITAL STOCK The following summary of the terms of our common stock may not be complete and is subject to, and qualified in its entirety by reference to, the terms and provisions of our amended and restated certificate of incorporation and our amend |
|
| March 31, 2023 |
Subsidiaries of the Registrant. EXHIBIT 21.1 SUBSIDIARIES OF FORTRESS BIOTECH, INC. Subsidiaries of Fortress Biotech, Inc. at December 31, 2022, with jurisdiction of incorporation or formation: ● Aevitas Therapeutics, Inc. (Delaware) ● Avenue Therapeutics, Inc. (Delaware) ● Cellvation, Inc. (Delaware) ● Checkpoint Therapeutics, Inc. (Delaware) ● Cyprium Therapeutics, Inc. (Delaware) ● Helocyte, Inc. (Delaware) ● Journey Medical |
|
| March 30, 2023 |
Exhibit 99.1 Fortress Biotech Reports Record 2022 Financial Results and Recent Corporate Highlights Fortress expects to file a total of three new drug applications in 2023 Record consolidated net revenue of $75.7 million for full-year 2022 FDA accepted for filing the Biologics License Application for cosibelimab in patients with metastatic or locally advanced cutaneous squamous cell carcinoma; PDU |
|
| March 30, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 30, 2023 Fortress Biotech, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-35366 (Commission File Number) 20- |
|
| March 13, 2023 |
FORTRESS BIOTECH, INC. 1111 Kane Concourse Suite 301 Bay Harbor Islands, FL 33154 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confi |
|
| March 3, 2023 |
FORTRESS BIOTECH, INC. 1111 Kane Concourse Suite 301 Bay Harbor Islands, FL 33154 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: x Preliminary Proxy Statement ¨ Confi |
|
| February 14, 2023 |
FBIO / Fortress Biotech Inc / Nantahala Capital Management, LLC - SC 13G/A Passive Investment SC 13G/A 1 tm236168d23sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* FORTRESS BIOTECH, INC. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 34960Q109 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the a |
|
| February 14, 2023 |
FBIO / Fortress Biotech Inc / KATZ DARYL - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) Under the Securities Exchange Act of 1934* (Amendment No. 1) Fortress Biotech, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 34960Q 109 (CUSIP Number) Daryl Katz c/o Katz Group Suite 2700 Edmonton Tower 10111 104 Avenue NW Edmonton AB T5J 0J4 Telephone |
|
| February 10, 2023 |
Exhibit 107.1 Calculation of Filing Fee Tables Form S-3 (Form Type) Fortress Biotech, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule(1) Amount Registered(2) Proposed Maximum Offering Price Per Unit(1) Maximum Aggregate Offering Price(1) Fee Rate Amount of Registration Fee Equity Common Stock, |
|
| February 10, 2023 |
As filed with the Securities and Exchange Commission on February 10, 2023 As filed with the Securities and Exchange Commission on February 10, 2023 Registration No. |
|
| February 9, 2023 |
16,642,894 Shares of Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-258145 PROSPECTUS SUPPLEMENT (to the Prospectus dated July 30, 2021) 16,642,894 Shares of Common Stock Pursuant to this prospectus supplement, the accompanying prospectus and securities purchase agreement (the “Securities Purchase Agreement”) we are offering 16,642,894 shares of our common stock $0.001 par value per share (the “Common Stock”) |
|
| February 9, 2023 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of February 7, 2023, between Fortress Biotech, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and condition |
|
| February 9, 2023 |
FBIO / Fortress Biotech Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Fortress Biotech Inc Title of Class of Securities: Common Stock CUSIP Number: 34960Q109 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: |
|
| February 9, 2023 |
Exhibit 10.2 February 7, 2023 To: Investors identified on the signature pages hereto Re: Common Stock Purchase Warrants in Designated Subsidiaries Ladies and Gentlemen: This letter agreement (the “Letter Agreement”) is by and between Fortress Biotech, Inc. (the “Company”), and the investors identified on the signature pages hereto (the “Investors”) and collectively the (“Parties”). Reference is ma |
|
| February 9, 2023 |
Form of Contingent Subsidiary Security Exhibit 10.3 THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR ANY STATE SECURITIES LAWS, AND MAY NOT BE SOLD, TRANSFERRED, ASSIGNED OR HYPOTHECATED UNLESS THERE IS AN EFFECTIVE REGISTRATION STATEMENT UNDER SUCH ACT AND ANY APPLICABLE STATE SECURITIES LAWS COVERING SUCH SECURITIES OR THE SALE IS MADE IN ACCORDANCE WITH AN EXEMPT |
|
| February 9, 2023 |
Exhibit 99.1 Fortress Biotech Announces Pricing of $13.9 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules Miami, FL – February 8, 2023 – Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress” or “Company”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates |
|
| February 9, 2023 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Sections 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 7, 2023 Fortress Biotech, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-35366 (Commission File Numb |
|
| January 13, 2023 |
CKPT / Checkpoint Therapeutics Inc / Fortress Biotech, Inc. - SC 13D/A Activist Investment SC 13D/A 1 tm233183-1sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 2) Under the Securities Exchange Act of 1934 CHECKPOINT THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.0001 Par Value Class A Common Stock, $0.0001 Par Value (Title of Class of Securities) 162828 206 (CUSIP Number) Fortress Biotech, Inc. c/o Lindsay A. |
|
| January 13, 2023 |
MBIO / Mustang Bio Inc / Fortress Biotech, Inc. - SC 13D/A Activist Investment SC 13D/A 1 tm233183-2sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 2) Under the Securities Exchange Act of 1934 MUSTANG BIO, INC. (Name of Issuer) Common Stock, $0.0001 Par Value (Title of Class of Securities) 62818Q104 (CUSIP Number) Fortress Biotech, Inc. c/o Lindsay A. Rosenwald, M.D. 1111 Kane Concourse, Suite 301 Bay Ha |
|
| January 6, 2023 |
ATXI / Avenue Therapeutics Inc / Fortress Biotech, Inc. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 2) Under the Securities Exchange Act of 1934 AVENUE THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.0001 Par Value (Title of Class of Securities) 05360L205 (CUSIP Number) Fortress Biotech, Inc. c/o Lindsay A. Rosenwald, M.D. 1111 Kane Concourse, Suite 301 Bay Harbor Islands, FL 33154 (781) 652- |
|
| December 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Sections 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 14, 2022 Fortress Biotech, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-35366 (Commission File Num |
|
| December 19, 2022 |
Exhibit 10.1 [FORM OF] INDEMNITY AGREEMENT THIS INDEMNITY AGREEMENT (this “Agreement”) dated as of [·], is made by and between FORTRESS BIOTECH, INC., a Delaware corporation (the “Company”), and Lucy Lu, M.D. (“Indemnitee”). RECITALS A.The Company desires to attract and retain the services of highly qualified individuals as directors, officers, employees and agents. B.The Company’s bylaws (the “By |
|
| December 19, 2022 |
Fortress Biotech Appoints Lucy Lu, M.D., to its Board of Directors Exhibit 99.1 Fortress Biotech Appoints Lucy Lu, M.D., to its Board of Directors Miami, FL – December 19, 2022 – Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today announced that Lucy Lu, M.D., has been appointed to its |
|
| November 14, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 14, 2022 Fortress Biotech, Inc. (Exact Name of Registrant as Specified in Charter) ? Delaware (State or Other Jurisdiction of Incorporation) 001-35366 (Commission File Nu |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? For the quarterly period ended September 30, 2022 OR ? ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? For the transition period from to Commission File Number 0 |
|
| November 14, 2022 |
Exhibit 99.1 ? Fortress Biotech Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights ? Net revenue for the nine months of 2022 increased 17.5% period-over-period to $59.3 million ? Cosibelimab BLA submission for metastatic and locally advanced cutaneous squamous cell carcinoma expected to be submitted by January 2023 ? Miami, FL ? November 14, 2022 ? Fortress Biotech, Inc. |
|
| November 4, 2022 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 31, 2022 Fortress Biotech, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-35366 (Commission File Number) 2 |
|
| October 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Sections 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 26, 2022 Fortress Biotech, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-35366 (Commission File Numb |
|
| October 28, 2022 |
Exhibit 10.1 [FORM OF] FORTRESS BIOTECH, INC. 2013 STOCK INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD AGREEMENT This Restricted Stock Unit Award Agreement (this ?Agreement?) is made and entered into between Fortress Biotech, Inc. (the ?Company?) and David Jin (?Grantee?), effective as of [?] (such date the ?Date of Grant?). This Agreement sets forth the terms and conditions associated with the Compa |
|
| October 21, 2022 |
? Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) Fortress Biotech, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule(1) Amount Registered(2) Proposed Maximum Offering Price Per Unit(1) Maximum Aggregate Offering Price(1) Fee Rate Amount of Registration Fee Equity Common Stock |
|
| October 21, 2022 |
As filed with the Securities and Exchange Commission on October 21, 2022 As filed with the Securities and Exchange Commission on October 21, 2022 Registration No. |
|
| August 17, 2022 |
US48115J1097 / JOURNEY MEDICAL CORP / Fortress Biotech, Inc. - SC 13G Passive Investment SC 13G 1 tmb-20220817xsc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Journey Medical Corporation (Name of Issuer) CLASS A COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 48115J109 (CUSIP Number) Fortress Biotech, Inc. c/o Lindsay A. Rosenwald, M.D. 1111 Kane C |
|
| August 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? For the quarterly period ended June 30, 2022 OR ? ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? For the transition period from to Commission File Number 001-35 |
|
| August 11, 2022 |
Exhibit 99.1 Fortress Biotech Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights Net revenue for the first half of 2022 increased 45.5% period-over-period to $42.8 million Positive results from registration-enabling study of cosibelimab in metastatic cutaneous squamous cell carcinoma presented at ASCO in June 2022; BLA submission expected YE 2022 Miami, FL ? August 11, 2 |
|
| August 11, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 11, 2022 Fortress Biotech, Inc. (Exact Name of Registrant as Specified in Charter) ? Delaware (State or Other Jurisdiction of Incorporation) 001-35366 (Commission File Numb |
|
| July 22, 2022 |
? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 21, 2022 Fortress Biotech, Inc. (Exact Name of Registrant as Specified in its charter) ? Delaware (State or Other Jurisdiction of Incorporation) 001-35366 (Commission File Nu |
|
| July 22, 2022 |
FORTRESS BIOTECH APPOINTS DAVID JIN AS CHIEF FINANCIAL OFFICER Exhibit 99.1 FORTRESS BIOTECH APPOINTS DAVID JIN AS CHIEF FINANCIAL OFFICER Miami, FL - July 22, 2022 - Fortress Biotech, Inc. (NASDAQ: FBIO) (?Fortress? or the ?Company?), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today announced the appointment of David Jin as Chief |
|
| July 11, 2022 |
? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 11, 2022 Fortress Biotech, Inc. (Exact Name of Registrant as Specified in Charter) ? Delaware (State or Other Jurisdiction of Incorporation) 001-35366 (Commission File Number |
|
| July 11, 2022 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT OF THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION, AS AMENDED, OF FORTRESS BIOTECH, INC. Fortress Biotech, Inc. (the ?Corporation?), a corporation organized and existing under and by virtue of the Delaware General Corporation Law (the ?DGCL?), does hereby certify: 1. The Amended and Restated Certificate of Incorporation of the Corporation, as amended, is |
|
| June 27, 2022 |
Exhibit 10.1 AMENDMENT TO THE COMPANY?S 2013 STOCK INCENTIVE PLAN TO INCREASE THE NUMBER OF SHARES OF COMMON STOCK AUTHORIZED FOR ISSUANCE THEREUNDER 3. STOCK SUBJECT TO THE PLAN (a) Subject to the provisions of Section 12 below, the maximum aggregate number of Shares which may be issued pursuant to all Awards (including Incentive Stock Options) is Sixteen Million (16,000,000) Shares. The Shares m |
|
| June 27, 2022 |
? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 21, 2022 Fortress Biotech, Inc. (Exact Name of Registrant as Specified in Charter) ? Delaware (State or Other Jurisdiction of Incorporation) 001-35366 (Commission File Number |
|
| May 17, 2022 |
? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ? Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? ? ? Preliminary Proxy Statement ? ? Confidential, for Use of the Commission Only (as permitted by R |
|
| May 12, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 12, 2022 Fortress Biotech, Inc. (Exact Name of Registrant as Specified in Charter) ? Delaware (State or Other Jurisdiction of Incorporation) 001-35366 (Commission File Number) |
|
| May 12, 2022 |
Exhibit 99.1 ? ? Fortress Biotech Reports First Quarter 2022 Financial Results and Recent Corporate Highlights ? Net revenue for first quarter of 2022 increased 106% period-over-period to $23.9 million, a company quarterly record ? Positive topline results from registration-enabling study of cosibelimab in metastatic cutaneous squamous cell carcinoma announced in January 2022; BLA submission expec |
|
| May 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? For the quarterly period ended March 31, 2022 OR ? ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? For the transition period from to Commission File Number 001-3 |
|
| May 2, 2022 |
? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6( |
|
| May 2, 2022 |
Table of Contents ? ? FORTRESS BIOTECH, INC. 1111 Kane Concourse Suite 301 Bay Harbor Island, FL 33154 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? ? SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ? ? ? ? Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Pr |
|
| April 20, 2022 |
Table of Contents ? ? FORTRESS BIOTECH, INC. 1111 Kane Concourse Suite 301 Bay Harbor Island, FL 33154 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? ? SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ? ? ? ? Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Pr |
|
| March 28, 2022 |
Subsidiaries of the Registrant. EXHIBIT 21.1 ? SUBSIDIARIES OF FORTRESS BIOTECH, INC. ? Subsidiaries of Fortress Biotech, Inc. at December 31, 2021, with jurisdiction of incorporation or formation: ? ? Aevitas Therapeutics, Inc. (Delaware) ? Avenue Therapeutics, Inc. (Delaware) ? Baergic Bio, Inc. (Delaware) ? Cellvation, Inc. (Delaware), formerly FBIO Acquisition Corp. I ? Checkpoint Therapeutics, Inc. (Delaware) ? Cyprium Ther |
|
| March 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 28, 2022 |
Exhibit 99.1 Fortress Biotech Reports Record 2021 Financial Results and Recent Corporate Highlights Record 2021: Net revenue of $68.8 million and proceeds from the successful monetization of our investment in Caelum Biosciences of $56.9 million1 2021 net loss attributable to common stockholders on a GAAP basis was $(64.7) million or $(0.79) per share; 2021 non-GAAP income attributable to common st |
|
| March 28, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 28, 2022 Fortress Biotech, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-35366 (Commission File Number) 20- |
|
| February 14, 2022 |
FBIO / Fortress Biotech Inc / Nantahala Capital Management, LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* FORTRESS BIOTECH, INC. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 34960Q109 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursu |
|
| February 10, 2022 |
FBIO / Fortress Biotech Inc / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Fortress Biotech Inc Title of Class of Securities: Common Stock CUSIP Number: 34960Q109 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1(b) ☐ Ru |
|
| December 7, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 3, 2021 Fortress Biotech, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-35366 (Commission File Number) 2 |
|
| November 24, 2021 |
As filed with the Securities and Exchange Commission on November 24, 2021. As filed with the Securities and Exchange Commission on November 24, 2021. Registration No. 333-255185 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 Post-Effective Amendment No. 3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 FORTRESS BIOTECH, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 2834 47-3828760 (State or Other Jurisdicti |
|
| November 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? For the quarterly period ended September 30, 2021 OR ? ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? For the transition period from to Commission File Number 0 |
|
| November 15, 2021 |
Exhibit 99.1 Fortress Biotech Reports Record Third Quarter 2021 Financial Results and Recent Corporate Highlights Net revenue for third quarter of 2021 increased 123% year-over-year to $21.1 million, a quarterly record Journey Medical Corporation, a Fortress partner company, launched its $35.2 million initial public offering AstraZeneca acquired Caelum Biosciences; Fortress received $56.9 million |
|
| November 15, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 15, 2021 Fortress Biotech, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-35366 (Commission File Number) |
|
| November 3, 2021 |
As filed with the Securities and Exchange Commission on November 3, 2021. As filed with the Securities and Exchange Commission on November 3, 2021. Registration No. 333-255185 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 Post-Effective Amendment No. 2 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 FORTRESS BIOTECH, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 2834 47-3828760 (State or Other Jurisdictio |
|
| October 27, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 27, 2021 Fortress Biotech, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-35366 (Commission File Number) 2 |
|
| October 19, 2021 |
As filed with the Securities and Exchange Commission on October 19, 2021. As filed with the Securities and Exchange Commission on October 19, 2021. Registration No. 333-255185 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 Post-Effective Amendment No. 2 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 FORTRESS BIOTECH, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 2834 47-3828760 (State or Other Jurisdictio |
|
| October 19, 2021 |
90 Park Avenue New York, NY 10016 212-210-9400 | Fax: 212-210-9444 90 Park Avenue New York, NY 10016 212-210-9400 | Fax: 212-210-9444 Mark F. McElreath Direct Dial: 212-210-9595 Email: [email protected] October 19, 2021 Ms. Christine Westbrook and Ms. Celeste Murphy Division of Corporation Finance Office of Life Sciences Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Fortress Biotech, Inc. Post-Effective Amendment No. 1 t |
|
| October 6, 2021 |
As filed with the Securities and Exchange Commission on October 6, 2021. As filed with the Securities and Exchange Commission on October 6, 2021. Registration No. 333-255185 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 Amendment No. 2 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 FORTRESS BIOTECH, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 2834 47-3828760 (State or Other Jurisdiction of (Primary St |
|
| October 6, 2021 |
EX-99.1 2 tm2129318d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Fortress Biotech Announces Closing of Acquisition of Caelum Biosciences by AstraZeneca Triggers upfront payment of approximately $150 million to Caelum shareholders, of which approximately $64 million is payable to Fortress Biotech1 New York, NY and Bordentown, NJ – October 6, 2021 – Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an in |
|
| October 6, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 5, 2021 Fortress Biotech, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-35366 (Commission File Number) 20 |
|
| September 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 28, 2021 Fortress Biotech, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-35366 (Commission File Number) |
|
| September 28, 2021 |
Changes in Registrant's Certifying Accountant, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 22, 2021 Fortress Biotech, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-35366 (Commission File Number) |
|
| September 24, 2021 |
Letter from BDO USA, LLP to the Securities and Exchange Commission dated September 22, 2021 Exhibit 16.1 Tel: 617-422-0700 One International Place Fax: 617-422-0909 Boston, MA 02110 www.bdo.com September 22, 2021 Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 We have been furnished with a copy of the response to Item 4.01 of Form 8-K for the event that occurred on September 20, 2021, to be filed by our former client, Fortress Biotech, Inc. We agree with the s |
|
| September 24, 2021 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 20, 2021 Fortress Biotech, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-35366 (Commission File Number) |
|
| August 27, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 26, 2021 Fortress Biotech, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-35366 (Commission File Number) 20 |
|
| August 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? For the quarterly period ended June 30, 2021 OR ? ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? For the transition period from to Commission File Number 001-35 |
|
| August 16, 2021 |
Exhibit 10.2 ? CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT BOTH (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. SUCH EXCLUDED INFORMATION HAS BEEN MARKED WITH ?[***]. ? ASSET PURCHASE AGREEMENT This ASSET PURCHASE AGREEMENT (this ?Agreement?) is made and entered into as of February 23, 2021 (the ?Effective Date?), by and between S |
|
| August 16, 2021 |
Certain identified information has been excluded from the document because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. |
|
| August 16, 2021 |
Exhibit 10.3 ? CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT BOTH (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. SUCH EXCLUDED INFORMATION HAS BEEN MARKED WITH ?[***]. ? ? ? ? ? ? ASSET PURCHASE AGREEMENT BETWEEN DERMIRA, INC. AND JOURNEY MEDICAL CORPORATION DATED AS OF MARCH 31, 2021 ? ? ? TABLE OF CONTENTS ? ? ? ? ? ? Page ? ? ? |
|
| August 16, 2021 |
Exhibit 99.1 Fortress Biotech Reports Record Second Quarter 2021 Financial Results and Recent Corporate Highlights Net revenue for second quarter of 2021 increased 89% year-over-year to $17.8 million, a quarterly record Rolling NDA submission for CUTX-101 for the treatment of Menkes disease expected to begin in the second half of 2021 On track to report top-line results from registration-enabling |
|
| August 16, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 16, 2021 Fortress Biotech, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-35366 (Commission File Number) 20 |
|
| July 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 27, 2021 Fortress Biotech, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-35366 (Commission File Number) 20-5 |
